First In-Body CRISPR Therapy Succeeds in Phase 3 Trial, Paving Way for One-Time Genetic Cures

For the first time since CRISPR gene editing was discovered, a therapy has successfully cured a genetic disease by editing DNA directly inside the human body in a late-stage clinical trial. In June 2026, Cambridge-based Intellia Therapeutics presented the results of its Phase 3 HAELO trial at the European Academy of Allergy and Clinical Immunology congress, simultaneously publishing the findings in the New England Journal of Medicine. The trial evaluated lonvoguran ziclumeran (lonvo-z), a one-time intravenous infusion designed to permanently rewrite a defective gene in patients with hereditary angioedema (HAE). The results establish a definitive proof-of-concept for in vivo gene editing, clearing the largest scientific hurdle that stood between CRISPR technology and broad clinical use.[1][2][3]

Hereditary angioedema is a rare, potentially life-threatening genetic disorder characterized by severe, unpredictable swelling in the limbs, face, gastrointestinal tract, and airways. The condition is driven by the overproduction of a peptide called bradykinin, which is regulated by kallikrein enzymes. For decades, patients have relied on chronic, lifelong prophylactic medications to manage the attacks. Lonvo-z takes a radically different approach: it uses CRISPR/Cas9 molecular scissors to permanently inactivate the kallikrein B1 (KLKB1) gene in the patient's liver cells, stopping the cascade at its genetic source.[2][3][4][7]

The clinical evidence from the 80-patient double-blind trial is striking. According to the New England Journal of Medicine publication, a single dose of lonvo-z reduced mean monthly HAE attacks by 87% compared to a placebo over a six-month evaluation period. More significantly, 62% of the patients who received the active treatment remained entirely attack-free and required no other medication during that timeframe, compared to just 11% in the placebo group. The therapy also reduced the need for on-demand rescue treatments by 89%.[1][2][6][7]

The primary claim validated by these results is that in vivo CRISPR delivery is both highly effective and safe in humans. Delivering gene-editing machinery directly into the bloodstream has long been considered the "holy grail" of genomic medicine, but it carries immense technical risks, primarily the danger of off-target edits or severe immune reactions. The HAELO trial utilized lipid nanoparticles (LNPs)—similar to the fat-based envelopes used in mRNA vaccines—to ferry the CRISPR components directly to the liver.[1][5]

Researchers from Amsterdam UMC, who helped lead the international trial, reported that the safety profile was highly favorable. The most frequent side effects were mild, temporary infusion-related reactions such as fatigue and headache, with no serious adverse events linked to the CRISPR mechanism itself. Furthermore, follow-up data from earlier Phase 1 and 2 cohorts indicates that the genetic edit remains stable and effective four years after the initial infusion, suggesting the "one-and-done" promise of the therapy is holding true.[7]

This in vivo success marks a paradigm shift from the first generation of CRISPR therapies. In late 2023, regulators approved Casgevy, the world's first commercial CRISPR treatment, for sickle cell disease. However, Casgevy is an ex vivo therapy: it requires extracting a patient's bone marrow stem cells, editing them in a laboratory, subjecting the patient to grueling chemotherapy to clear their existing marrow, and then reinfusing the edited cells.[1]

The physical and logistical toll of ex vivo editing restricts its use to specialized transplant centers and patients healthy enough to survive the conditioning regimen. Lonvo-z bypasses this entirely. By letting the body do the work, the treatment is reduced to a standard outpatient intravenous infusion. This transition from a multi-month hospitalization to a single clinic visit fundamentally alters the accessibility and scalability of genomic medicine.[1][4]

While lipid nanoparticles have proven highly effective at targeting the liver, a secondary claim emerging in the field is that the delivery bottleneck for other organs is rapidly being solved. LNPs tend to accumulate naturally in the liver, making it an ideal target for diseases like HAE. However, reaching the brain, heart, or muscle tissue requires different delivery vehicles, with adeno-associated viruses (AAVs) being the leading candidate.[1][5][8]

The central challenge with AAV delivery has been a strict payload limit. Standard CRISPR enzymes, such as Cas9, are physically too large to fit efficiently inside the viral capsid alongside their necessary guide RNAs. This size constraint has historically forced researchers to use complex dual-vector systems or abandon AAVs altogether for certain in vivo applications.[5][8]

Recent evidence suggests this geometric barrier has been broken. In April 2026, an NIH-funded research team at the University of Texas at Austin published a breakthrough in Nature Structural & Molecular Biology, detailing the discovery and optimization of a compact CRISPR enzyme called Al3Cas12f. This naturally occurring nuclease is approximately one-third the size of Cas9, allowing it to easily package into a single AAV vector.[5][8]

The UT Austin team engineered an enhanced variant of this miniature enzyme that achieved editing efficiencies exceeding 80% across multiple genomic targets in human cells. By solving the spatial constraints of viral vectors, ultra-compact enzymes like Al3Cas12f provide the missing technological puzzle piece required to expand in vivo CRISPR therapies to tissues that lipid nanoparticles cannot reach, such as the central nervous system.[5][8]

As the underlying science matures, a third claim is that regulatory frameworks are actively adapting to accommodate permanent genetic cures. Intellia has already initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration for lonvo-z. This rolling review process, enabled by the therapy's Regenerative Medicine Advanced Therapy (RMAT) designation, allows the company to submit sections of the application incrementally, accelerating the FDA's evaluation.[4]

Intellia is targeting a commercial launch for lonvo-z in the first half of 2027. If approved, it will be the first in vivo CRISPR therapy to reach the market, setting the regulatory and pricing precedents for a massive pipeline of subsequent treatments. Competitors are already advancing similar in vivo programs targeting cardiovascular disease, utilizing both standard CRISPR and newer base-editing technologies.[1][4]

Despite the overwhelming clinical success, transparent uncertainties remain. The foremost unknown is the multi-decade durability of the edit. While four-year data shows no waning of efficacy, liver cells regenerate over time, and it remains to be seen if the edited cell population will maintain dominance over a patient's entire lifespan. Additionally, the healthcare system has not yet finalized a sustainable economic model for one-time curative therapies that eliminate the need for decades of expensive chronic medications.[7]

Nevertheless, the HAELO trial results represent a watershed moment in human medicine. The ability to safely inject a programmable molecular machine into a patient's bloodstream, navigate it to a specific organ, and permanently correct a disease-causing genetic error is no longer a theoretical projection. It is now a validated clinical reality, opening the door to a future where genetic diseases are treated at their root cause with a single dose.[1][7]